VAERS Explorer
Back to explore

Report #2891110

Received Mar 30, 2026

A note on interpretation. VAERS reports are unverified and may be incomplete or coincidental. A report does not establish that a vaccine caused an event, and counts should not be used to calculate incidence or infer causation. Full disclaimer

Overview

Sex
Male
Age
0.3 yrs
State
CO
Recovered
Unknown
Vaccinated
Mar 23, 2026
Onset
Mar 23, 2026
Days to onset
0
Hospital days

Vaccines (1)

TypeNameManufacturerDoseLotRoute / Site
DTAPIPVDTAP + IPV (KINRIX)GLAXOSMITHKLINE BIOLOGICALS23c423

Symptoms (1)

Product administered to patient of inappropriate age

Symptom narrative

Administration of Kinrix as second dose/had accidentally given a 4 month old patient; Administration of Kinrix as second dose/had accidentally given a 4 month old patient; This non-serious case was reported by a other health professional via call center representative and described the occurrence of inappropriate age at vaccine administration in a 4-month-old male patient who received DTPa-IPV (Kinrix) (batch number 3c423, expiry date 06-SEP-2027) for prophylaxis. Previously administered products included Pediarix (1st dose received on an unknown date). On 23-MAR-2026, the patient received the 2nd dose of Kinrix. On 23-MAR-2026, an unknown time after receiving Kinrix, the patient experienced inappropriate age at vaccine administration (Verbatim: Administration of Kinrix as second dose/had accidentally given a 4 month old patient) and inappropriate schedule of vaccine administered (Verbatim: Administration of Kinrix as second dose/had accidentally given a 4 month old patient). The outcome of the inappropriate age at vaccine administration and inappropriate schedule of vaccine administered were not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 23-MAR-2026 A healthcare professional called in to report that they had accidentally given a 4-month-old patient, and they wanted to receive data on the validity of the dose. The first dose was Pediarix.